| scholarly article | Q13442814 |
| P2093 | author name string | C Chen | |
| S Weinmann | |||
| K A B Goddard | |||
| K Richert-Boe | |||
| C Wax | |||
| J Bulkley | |||
| P2860 | cites work | ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer | Q72682030 |
| HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15 | Q73308218 | ||
| ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer | Q73505916 | ||
| Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers | Q74195368 | ||
| Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B | Q77156165 | ||
| erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer | Q77331949 | ||
| erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer | Q77331953 | ||
| Update: NCCN practice guidelines for the treatment of breast cancer. National Comprehensive Cancer Network | Q77888377 | ||
| Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer | Q79794472 | ||
| A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer | Q79794476 | ||
| Influence of health insurance status on inclusion of HER-2/neu testing in the diagnostic workup of breast cancer patients | Q81041278 | ||
| Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab | Q81151636 | ||
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Breast cancer. Clinical practice guidelines in oncology | Q28308245 | ||
| Cancer statistics, 2007 | Q29547293 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer | Q29617440 | ||
| Automated inter-rater reliability assessment and electronic data collection in a multi-center breast cancer study | Q31116173 | ||
| Challenges to the translation of genomic information into clinical practice and health policy: Utilization, preferences and economic value | Q34022038 | ||
| Closing the evidence gap in the use of emerging testing technologies in clinical practice | Q34022044 | ||
| When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer | Q34220459 | ||
| Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer | Q34496969 | ||
| HER2 testing in breast cancer: NCCN Task Force report and recommendations. | Q36524447 | ||
| HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients | Q36614830 | ||
| American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer | Q36678853 | ||
| HER2 testing and subsequent trastuzumab treatment for breast cancer in a managed care environment | Q37580586 | ||
| NCCN breast cancer clinical practice guidelines in oncology: an update. | Q37606431 | ||
| Review of testing and use of adjuvant trastuzumab across a cancer network--are we treating the right patients? | Q37720045 | ||
| HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas | Q38474138 | ||
| Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. | Q38485006 | ||
| Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease | Q40630247 | ||
| NCCN Practice Guidelines for Breast Cancer. | Q40725293 | ||
| Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients | Q43675467 | ||
| Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial | Q43739514 | ||
| Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer | Q44298529 | ||
| Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer | Q44358950 | ||
| Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma | Q44375021 | ||
| A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer | Q46586619 | ||
| HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues | Q47612892 | ||
| HER-2 testing in breast cancer using parallel tissue-based methods | Q47685189 | ||
| Evaluating HER2 amplification and overexpression in breast cancer. | Q52936177 | ||
| HER2 and responsiveness of breast cancer to adjuvant chemotherapy. | Q54600960 | ||
| HER2 testing, adjuvant trastuzumab use and results. Our experience in South Wales. | Q54656260 | ||
| HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer | Q57578634 | ||
| Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre | Q61624905 | ||
| c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases | Q71692738 | ||
| Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma | Q72174351 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 1-10 | |
| P577 | publication date | 2011-05-03 | |
| P1433 | published in | Public Health Genomics | Q15766289 |
| P1476 | title | HER2 evaluation and its impact on breast cancer treatment decisions | |
| P478 | volume | 15 |
| Q34248282 | Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers |
| Q37573749 | Closing the personalized medicine information gap: HER2 test documentation practice |
| Q36312110 | Distinct ErbB2 receptor populations differentially interact with beta1 integrin in breast cancer cell models |
| Q44272543 | Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials |
| Q53839396 | Real-World Data on Health-Related Quality of Life Assessment in Patients With Breast Cancer Receiving Subcutaneous Trastuzumab. |
| Q33862786 | Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update |
| Q36969368 | Symptomatic metastasis prediction with serial measurements of CA 15.3 in primary breast cancer patients |
| Q90611117 | The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas |
Search more.